Summary:
A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled,
Parallel-Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen
of Fremanezumab Versus Placebo for the Prevention of Persistent Posttraumatic Headache
Qualified Participants Must:
• The patient is a man or woman 18 to 70 years of age
Qualified Participants May Receive:
Compensation for time and travel